Abstract
Cyclosporin A has been used to treat graft versus host reactions in eight patients of whom seven had had marrow grafts for acute leukemia, and one for marrow aplasia. All grafts were MHC-MLR compatible. The drug, in doses up to 2100 mg daily, has been given either by intramuscular injection, or by mouth in capsules or dissolved in olive oil.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Powles, R. L., Barrett, A. J., Clink, H., Kay, H. E. M., Sloane, J., McElwain, T. J.: Cyclosporin A for the treatment of graft versus host disease in man. Lancet 1978 II, 1327–1331
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kay, H.E.M., Powles, R.L., Sloane, J.P., Farthing, M.G. (1980). Cyclosporin A in Human Bone Marrow Grafts. In: Thierfelder, S., Rodt, H., Kolb, H.J. (eds) Immunobiology of Bone Marrow Transplantation. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 25. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67319-1_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-67319-1_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-09405-0
Online ISBN: 978-3-642-67319-1
eBook Packages: Springer Book Archive